Invesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life.Be the first to know! Sign up for Invesco US Blog and get expert investment views as they post.Disclosure for all Invesco US articles: Before investing, carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. The information provided is for educational purposes only and does not constitute a ...

Core Viewpoint - The Stock Exchange of Thailand (SET) and Nasdaq have announced an expanded strategic technology partnership aimed at modernizing Thailand's capital markets, focusing on enhancing market resilience, integrity, and aligning with global standards through the use of Nasdaq's AI capabilities [1][2]. Group 1: Partnership Objectives - The collaboration will promote the adoption of Nasdaq's risk and surveillance platforms within SET's member community to drive consistent infrastructure across the market ecosystem [2]. - The initiative aims to enhance systemwide efficiency, transparency, and risk management, benefiting from common market infrastructure and Nasdaq's ongoing investments in modernization [2][3]. Group 2: Market Impact - The partnership is expected to strengthen liquidity, transparency, and integrity in Thailand's capital markets, fostering trust and investor confidence [3]. - By adopting advanced risk and surveillance solutions, SET aims to improve its ability to detect market abuse and monitor trading activities, reinforcing Thailand's leadership in ASEAN's capital markets [3][4]. Group 3: Nasdaq's Global Reach - Nasdaq's technology is utilized by 97% of globally systematically important banks, half of the world's top 25 stock exchanges, and over 3,800 clients in the financial services industry [3]. - The partnership reflects Nasdaq's commitment to advancing industry-wide modernization through deep strategic relationships and mission-critical solutions [4]. Group 4: Future Vision - Together, SET and Nasdaq are laying the foundation for a robust, future-ready capital market ecosystem, enhancing Thailand's position as a regional innovation leader and financial hub [5].

Core Viewpoint - Hepion Pharmaceuticals has transitioned from developing treatments for chronic liver diseases to focusing on diagnostic tests, while facing delisting from Nasdaq due to non-compliance with listing standards [1][2]. Company Overview - Hepion Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that was previously developing treatments for non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) [1]. - The company's primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which has shown efficacy in reducing liver fibrosis and HCC tumor burden in experimental models [3]. Recent Developments - On May 9, 2025, the company received a notice from Nasdaq indicating that its shares would be delisted due to failure to maintain a minimum bid price of $1.00 per share and being classified as a public shell [1]. - Following the suspension of trading on Nasdaq, the company's shares are expected to be quoted on the OTC Markets Group under the existing symbol "HEPA" [2]. - Hepion announced a license agreement with New Day Diagnostics LLC on May 9, 2025, to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori, and HCC, with some tests already having CE marks for sale in Europe [5]. Clinical Trials - In April 2024, Hepion decided to wind down its ASCEND-NASH clinical trial, which was a Phase 2b study aimed at evaluating the safety and efficacy of Rencofilstat over 12 months, with a target enrollment of 336 subjects [4]. - Enrollment in the trial was paused in April 2023 after 151 subjects were randomized, and approximately 80 subjects have completed their Day 365 visits [4].

Positions American Bitcoin to become a publicly traded vehicle for low-cost Bitcoin accumulation at scaleMIAMI, May 12, 2025 /PRNewswire/ -- American Bitcoin Corp. ("American Bitcoin" or the "Company"), a Bitcoin accumulation platform focused on building America's Bitcoin infrastructure backbone, today announced that it has entered into a definitive merger agreement with Gryphon Digital Mining, Inc. (Nasdaq: GRYP) ("Gryphon") pursuant to which Gryphon will acquire American Bitcoin in a stock-for-stock merge ...

Core Viewpoint - Tech stocks are experiencing a rally, presenting investment opportunities in major companies despite previous downturns [1][2][3] Group 1: Amazon - Amazon Web Services (AWS) generated $29.3 billion last quarter, reflecting a 17% year-over-year growth, although slower than competitors [5] - The company plans over $100 billion in capital expenditures by 2025, primarily to increase AWS capacity and invest in custom AI silicon solutions [6] - Shipping expenses grew only 3% year over year while paid units increased by 8%, indicating improved logistics efficiency [8] - Amazon's enterprise value is less than 3 times the 2025 sales estimates, approximately 10% below its long-term average, suggesting a favorable valuation for investors [10] Group 2: Lam Research - Lam Research is a leading manufacturer of semiconductor fabrication equipment, with 43% of its revenue from memory chip manufacturers [11][12] - The company reported a 24% revenue growth last quarter and anticipates further growth in Q2, despite tariff uncertainties [13] - Lam is expected to increase its market share in wafer fabrication equipment, outpacing the semiconductor industry's growth [14] - The stock trades at 19 times forward earnings estimates, with management projecting double-digit earnings growth over the next four years [15] Group 3: Meta Platforms - Meta Platforms increased its capital spending plans for the year to between $64 billion and $72 billion, focusing on AI investments [16] - The company reported a 16% revenue growth last quarter, driven by strong engagement and rising ad prices [17] - AI tools are expected to enhance marketing capabilities and customer service, potentially generating significant revenue from Meta's messaging apps [18] - Meta has consistently produced over $10 billion in free cash flow for eight consecutive quarters, supporting ongoing investments in technology [19] - The stock trades at 23 times forward earnings estimates, with potential for double-digit earnings growth, indicating it is undervalued [20]

Core Points - Shopify Inc. will be added to the Nasdaq-100 Index and the Nasdaq-100 Equal Weighted™ Index on May 19, 2025, replacing MongoDB, Inc. [1] - MongoDB, Inc. will be removed from multiple Nasdaq indices, including the Nasdaq-100 Tech Sector™ Index and others, on the same date [2] Company Information - Nasdaq is a leading global technology company that provides services to corporate clients, investment managers, banks, brokers, and exchange operators, focusing on improving liquidity, transparency, and integrity in the global economy [4]

Core Viewpoint - Femto Technologies Inc. has received a notification from Nasdaq regarding the delisting of its securities due to significant shareholder dilution resulting from a recent private placement transaction [1][2]. Group 1: Company Actions - The company intends to appeal Nasdaq's determination to a Hearings Panel, which will stay the suspension of its securities pending the Panel's decision [3]. Group 2: Company Background - Femto Technologies Inc. is a Femtech company focused on wellness technology, emphasizing AI-driven solutions to enhance well-being [4]. - The company is known for its product Sensera, a feminine wellness device that integrates machine learning and AI to provide a holistic self-care experience [5].

Summary of Key Points Core Viewpoint - The total short interest in Nasdaq securities has increased, indicating a growing bearish sentiment among investors as of the settlement date of April 30, 2025 [3]. Group 1: Nasdaq Global Market - Short interest in 3,156 Nasdaq Global Market securities totaled 13,300,707,903 shares, up from 13,211,633,004 shares in the previous reporting period [1]. - The average short interest represents 2.40 days compared to 1.76 days in the prior reporting period [1]. Group 2: Nasdaq Capital Market - Short interest in 1,636 securities on The Nasdaq Capital Market reached 2,645,060,429 shares, an increase from 2,609,354,721 shares in the previous period [2]. - The average daily volume remained stable at 1.00 day for both reporting periods [2]. Group 3: Overall Nasdaq Securities - Total short interest across all 4,792 Nasdaq securities was 15,945,768,331 shares, compared to 15,820,987,725 shares in the previous reporting period [3]. - The average daily volume for all securities increased to 1.92 days from 1.52 days in the prior period [3]. Group 4: Short Sale Definition - A short sale is defined as the sale of a security that the seller does not own or any sale consummated by the delivery of a borrowed security [4].

Core Viewpoint - MetaVia Inc. has announced a private placement expected to generate approximately $10.0 million in gross proceeds, aimed at supporting the clinical development of its obesity treatment, DA-1726 [1][2]. Group 1: Private Placement Details - The offering includes the purchase of 9,479,345 shares of common stock at $0.71 per share and 4,605,162 pre-funded warrants at $0.709 each, with an exercise price of $0.001 [2]. - The private placement is priced at-the-market under Nasdaq rules, with the closing expected around May 12, 2025, subject to customary conditions [2]. Group 2: Regulatory and Compliance Information - The securities are being offered to certain institutional accredited investors and are not registered under the Securities Act, thus cannot be sold in the U.S. without an effective registration statement or applicable exemption [3]. - MetaVia plans to file a registration statement with the SEC for the resale of the shares issued in the private placement and to obtain stockholder approval for the underlying shares of the pre-funded warrants [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [5]. - DA-1726 is a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, potentially leading to superior weight loss compared to selective GLP1R agonists [5]. - DA-1241 is a GPR119 agonist that promotes the release of gut peptides and has shown positive effects on liver inflammation and glucose metabolism in pre-clinical studies [5].

Group 1 - KWESST Micro Systems Inc. has regained compliance with Nasdaq's minimum bid price requirement after achieving a closing bid price of at least USD$1.00 per common share for 10 consecutive business days from April 24, 2025, to May 7, 2025 [1][2] - The listing matter regarding the company's compliance has been closed, allowing its common shares and public warrants to continue trading on Nasdaq under the symbols "KWE" and "KWESW" respectively [2] Group 2 - KWESST develops and commercializes next-generation tactical systems for military and security forces, focusing on digitization for real-time situational awareness and targeting information [3] - The company's product offerings include countermeasures against electronic detection, lasers, and drones, which can operate independently or integrate with existing systems [3] - KWESST also has a proprietary non-lethal product line branded PARA OPSTM, applicable across various segments including law enforcement [3]